Adherence to intravenous chemotherapy in African American and white women with early-stage breast cancer

Cancer Nursing

Volumn 38, Issue 2, 2015, Pages 89-98

  Wells, Jessica S ^a   Strickland, Ora L ^b   Dalton, Jo Ann ^a   Freeman, Sarah ^a  

^a EMORY UNIVERSITY   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Breast cancer; Cancer disparities; Chemotherapy adherence

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CAUCASIAN; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL FEATURE; CONTROLLED STUDY; COPING BEHAVIOR; DISEASE SEVERITY; DRUG WITHDRAWAL; DUAL ELIGIBILITY (HEALTH INSURANCE); EARLY CANCER; FEMALE; HEALTH BELIEF; HEALTH INSURANCE; HUMAN; INJURY SCALE; MAJOR CLINICAL STUDY; MEDICARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT EDUCATION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RELIGION; SOCIAL SUPPORT; TREATMENT OUTCOME; BREAST NEOPLASMS; COMPLICATION; DEPRESSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NURSING; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; UTILIZATION; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DEPRESSIVE DISORDER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; SOCIAL SUPPORT;

EID: 84924336284     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0000000000000139     Document Type: Article

References (53)

1. Berg JS, Dischler J, Wagner D, Raia J, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27(Suppl):5-24.
2. Sabate E. Adherence to Long-term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. http://www.who.int/chronic-conditions/en/adherence?report.pdf. Accessed February 2, 2012.
3. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer. 2000;88(1):114-123.
4. Woodward WA, Huang EH, McNeese MD, et al. African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer. 2006;107(11):2662-2668.
5. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006;166(20):2244-2252.
6. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24(9):1357-1362.
7. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23(27):6639-6646.
8. Berger D, Braverman A, Sohn CK, Morrow M. Patient compliance with aggressive multimodal therapy in locally advanced breast cancer. Cancer. 1988;61(7):1453-1456.
9. Dobie SA, Baldwin L-M, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006;98(9):610-619.
10. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65(1):17-22.
11. Andic F, Godette K, O'Regan R, et al. Treatment adherence and outcome in women with inflammatory breast cancer. Cancer. 2010;117(24):5485-5492.
12. American Cancer Society. Breast Cancer Facts and Figures 2011-2012. Atlanta, GA: ACS; 2012.
13. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53(4):1020-1024.
14. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521.
15. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10-15.
16. Early Breast Cancer Trialist Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
17. Early Breast Cancer Trialist Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339(8784):1-15.
18. Lee Y. Adjuvant chemotherapy (CMF) for breast carcinoma: patient's compliance and total dose achieved. Am J Clin Oncol. 1983;6:25-30.
19. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 earlystage breast cancer patients. J Clin Oncol. 2010;28(27):4120.
20. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984;100(2):258-268.
21. PASS User's Guide: PASS 2000: Power Analysis and Sample Size for Windows [computer program]. Kaysville, UT: NCSS; 2000.
22. Norbeck JS, Lindsey AM, Carrieri VL. The development of an instrument to measure social support. Nurs Res. 1981;30(5):264-269.
23. Norbeck JS, Lindsey AM, Carrieri VL. Further development of the Norbeck Social Support Questionnaire: normative data and validity testing. Nurs Res. 1983;32(1):4-9.
24. Cohen J, Lazarus R. Social Support Questionnaire. Berkeley, CA: University of California; 1977.
25. Schutz W. FIRO-B. Palo Alto, CA: Consulting Psychologists Press; 1977.
26. Pargament KI, Koenig HG, Perez LM, Pargament KI, Koenig HG, Perez LM. The many methods of religious coping: development and initial validation of the RCOPE. J Clin Psychol. 2000;56(4):519-543.
27. Koenig HG, Pargament KI, Nielsen J. Religious coping and health status in medically ill hospitalized older adults. J Nerv Mental Dis. 1998;186(9):513.
28. Pargament KI, Smith BW, Koenig HG, Perez L. Patterns of positive and negative religious coping with major life stressors. J Sci Stud Religion. 1998;37(4):710-724.
29. Stager JL. The Comprehensive Breast Cancer Knowledge Test: validity and reliability. J Adv Nurs. 1993;18(7):1133-1140.
30. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The Memorial Symptom Assessment Scale Short Form (MSAS-SF). Cancer. 2000;89(5):1162-1171.
31. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
32. Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychom Res. 1999;46(5):437-443.
33. McNair DM, Lorr M, Droppleman LF. Profile of Mood States, POMS. 2nd ed. San Diego, CA: Educational and Industrial Testing Service; 1981.
34. Spielberger CD, Gorsuch RL, Luschene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
35. Ware JE, Kosinski M, Keller SD. SF-36 Physical And Mental Health Summary Scales: A Users Manual. Boston, MA: The Health Institute, New England Medical Center; 1994.
36. Champion VL. Instrument development for health model constructs. Adv Nurs Sci. 1984;6(3):73-85.
37. Powe BD. Cancer fatalism among elderly Caucasians and African Americans. Oncol Nurs Forum. 1995;22:1355-1359.
38. SPSS Advanced Models 19.0 [computer program]. Chicago, IL: SPSS Inc; 2011.
39. Lipscomb J, Gillespie TW, Goodman M, et al. Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat. 2012;133(1):285-296.
40. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329(5):326-331.
41. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94(7):490-496.
42. Roetzheim RG, Gonzalez EC, Ferrante JM, Pal N, Van Durme DJ, Krischer JP. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer. 2000;89(11):2202-2213.
43. Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A, Vlahos L. Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life. Qual Life Res. 2005;14(8):1825-1833.
44. Boehmke MM, Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs. 2005;28(5):382-389.
45. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage. 1999;18(4):233-242.
46. Payne R, Medina E, Hampton JW. Quality of life concerns in patients with breast cancer: evidence for disparity of outcomes and experiences in pain management and palliative care among African-American women. Cancer. 2003;97(1 suppl):311-317.
47. Badger TA, Braden CJ, Mishel MH. Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer. Oncol Nurs Forum. 2001;28(3):567-574.
48. Arndt V, Stegmaier C, Ziegler H, Brenner H. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. Cancer. 2006;107(10):2496-2503.
49. Revenson TA, Pranikoff JR. A contextual approach to treatment decision making among breast cancer survivors. Health Psychol. 2005;24(4 suppl): S93-S98.
50. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97-102.
51. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215-220.
52. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42(14):2271-2276.
53. Heath KV, Singer J, O'Shaughnessy MV, Montaner JSG, Hogg RS. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(2):211-217.